Science

Global Dry Eye Syndrome Drugs Market Research 2021-2025 | Industry Impact Analysis | Technavio

Thursday, January 21, 2021 - 8:28pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005893/en/
    Technavio has announced its latest market research report titled Global Dry Eye Syndrome Drugs Market 2021-2025 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your business?
  • The report on the dry eye syndrome drugs market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The dry eye syndrome drugs market analysis includes the product and geography landscape.
  • This study identifies the changing lifestyle and rising cases of diseases contributing to dry eye syndrome as one of the prime reasons driving the dry eye syndrome drugs market growth during the next few years.

SCIEX Acquires Intabio, a developer of precision solutions for biotherapeutic analysis through imaged cIEF-MS

Thursday, January 21, 2021 - 5:00pm

Blaze enables the direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins.

Key Points: 
  • Blaze enables the direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins.
  • Imaged cIEF-MS technology provides a groundbreaking solution for those looking for better and faster tools to characterize their increasingly complex biomolecules.
  • The Blaze System coupled to high-resolution mass spectrometry provides a streamlined approach that can reduce lengthy sample prep and deliver increased sample throughput.
  • SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all.

New Deep Learning Discovery Paves Way for AI Interpretation of Brainwave Data

Thursday, January 21, 2021 - 4:00pm

Machine learning has the potential to relieve some of this burden, but EEG data is extremely multidimensional and can be expensive, and time-consuming to annotate.

Key Points: 
  • Machine learning has the potential to relieve some of this burden, but EEG data is extremely multidimensional and can be expensive, and time-consuming to annotate.
  • This means there are typically not enough labelled examples for supervised deep neural networks to learn from in order to create an efficient AI.
  • While labelled-EEGs identifying sleep stages and brain activity are scarce, there is ample unlabeled data that exists.
  • Banville found that when limited numbers of labelled data were available, his self-supervised learning approach outperformed traditional supervised learning methods that rely purely on labelled data.

Reliatrace, Inc. Announces Patent for Self-Regulating Flexible Heating Device

Thursday, January 21, 2021 - 3:33pm

10,856,365 for a Self-Regulating Flexible Heating Device.

Key Points: 
  • 10,856,365 for a Self-Regulating Flexible Heating Device.
  • With this technology, the risk of overheating is greatly reduced compared with alternative heating methods using thermostats or other temperature controls.
  • This Self-Regulating Flexible Heating Device has already been used in the beauty industry.
  • While Reliatrace primarily works with B2B clients, earlier this year the company launched its first direct-to-consumer product using its patented Self-Regulating Flexible Heating Device in a new tool for bakers.

AltaSea & Flying Lion Launch Scientific and Educational Partnership to Develop an “Unmanned Aircraft System Center of Excellence”

Thursday, January 21, 2021 - 3:30pm

FLI, which started its partnership on January 15, joins two organizations with aligning missions to accelerate scientific collaboration and transform the rapidly-growing Blue Economy at AltaSea.

Key Points: 
  • FLI, which started its partnership on January 15, joins two organizations with aligning missions to accelerate scientific collaboration and transform the rapidly-growing Blue Economy at AltaSea.
  • "Flying Lion will be an important addition to our campus as we continue our leadership in the Blue Economy, said AltaSea CEO Tim McOsker.
  • The synergy between AltaSeas campus and Flying Lion UAS expertise creates an optimal environment to jointly develop breakthrough ocean-related research and discovery solutions to environmental problems, said Flying Lion CEO Barry Brennan.
  • Were pleased to welcome Flying Lion and its Unmanned Aircraft System (UAS) Center of Excellence to AltaSea at the Port of Los Angeles.

PWNHealth Introduces New Patient Support Program to Bolster National COVID-19 Vaccination Rollout

Thursday, January 21, 2021 - 2:37pm

This month, PWN began rolling out its COVID-19 vaccination support program in collaboration with CIC Health, a Cambridge, Mass.-based health tech company offering COVID-19 testing and vaccination services.

Key Points: 
  • This month, PWN began rolling out its COVID-19 vaccination support program in collaboration with CIC Health, a Cambridge, Mass.-based health tech company offering COVID-19 testing and vaccination services.
  • CIC Health has been selected by the Commonwealth of Massachusetts to operate New England's first mass vaccination site at Gillette Stadium in Foxborough.
  • PWNs COVID-19 vaccination support program is now available nationwide.
  • PWN's vaccination program will incorporate CDC-supported technologies to empower personalized check-ins and streamline side effect reporting with recipients.

Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Thursday, January 21, 2021 - 2:00pm

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the first adult participants have been dosed in a Phase 2 study of MV-012-968, the companys intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV).
  • Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV.
  • Meissa plans to initiate a Phase 1c study in sero-negative infants in the first half of this year.
  • Meissa is advancing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Worldwide Clinical Trials Moves Headquarters to Research Triangle Park

Thursday, January 21, 2021 - 2:05pm

Worldwide Clinical Trials, Inc. , (Worldwide) an award-winning, full-service, midsize, global CRO, has moved its corporate headquarters from Morrisville, N.C., to Frontier RTP , the innovation campus located in the heart of Research Triangle Park (RTP) in North Carolina.

Key Points: 
  • Worldwide Clinical Trials, Inc. , (Worldwide) an award-winning, full-service, midsize, global CRO, has moved its corporate headquarters from Morrisville, N.C., to Frontier RTP , the innovation campus located in the heart of Research Triangle Park (RTP) in North Carolina.
  • There is no such thing as a one-size-fits-all solution for a clinical trial, or for an employees choice of workspace, said Joy Clark, chief people, strategy and culture officer for Worldwide Clinical Trials.
  • Yet, that will not stop us from making investments like this that matter, said Peter Benton, president and chief operating officer, Worldwide Clinical Trials.
  • RTP welcomes Worldwide Clinical Trials into our diverse community of over 100 companies in Frontier RTP, says Scott Levitan, president and CEO of the Research Triangle Foundation, the organization that develops and manages Research Triangle Park.

RapidAI Enhancing Stroke Care Across Australia

Thursday, January 21, 2021 - 2:00pm

RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.

Key Points: 
  • RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.
  • Australia is a vast country and I am delighted to see more people having access to faster care irrespective of their postcode.
  • RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe.
  • RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.

Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate

Thursday, January 21, 2021 - 1:43pm

The prevention arms will assess Hexagens ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.

Key Points: 
  • The prevention arms will assess Hexagens ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.
  • While those who receive a vaccination may be protected if exposed, vaccines are not the end of this disease, said Bradley Burnam, CEO of Turn Therapeutics.
  • Turn Therapeutics is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care.
  • Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.